ADVL1416, A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors
A study for children with refractory solid tumors, including CNS tumors using study drug ramucirumab
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ5801
U.S. Govt. ID: NCT02564198
Contact: Alice Lee, MD: 212-305-5808 / al2041@cumc.columbia.edu
Additional Study Information: The goals of this study are to find the highest safe dose of ramucirumab that can be given without causing severe side effects, to learn what kind of side effects ramucirumab can cause, to learn more about the effects of ramucirumab on cells and proteins in the blood and to determine whether ramucirumab is a beneficial treatment for patients with solid tumors.
This study is closed
Investigator
Alice Lee, MD
Do You Qualify?
Has your child been diagnosed with solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Alice Lee, MD
al2041@cumc.columbia.edu
212-305-5808
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE